Primary Renal Cell Carcinoma

St. Joseph’s Hospital and Medical Center CyberKnife® Team:
Radiation Oncologist: John Kresl, M.D., Ph.D.
Medical Physicist: Raymond F. Rodebaugh, Ph.D.
Radiation Therapist: William Howe Jr., R.T.(T.)
CyberKnife Center: St. Joseph’s Hospital and Medical Center
Phoenix, AZ

Case study:

Outcome and Follow-Up

Three months after CyberKnife treatment, CT scan of the abdomen revealed an unchanged 3-4 cm lesion in the upper pole of the right kidney with no evidence of retroperitoneal adenopathy. There was no evidence of recurrent tumor in the left renal fossa. A PET scan confirmed no evidence of metastatic disease. Creatinine (2.3 mg/dl) and BUN (36 mg/dl) levels remained stable.

Nine months after CyberKnife treatment, the patient had a CT scan revealing an unchanged 4 cm low density mass located in the upper pole of the right kidney and a negative chest X-ray. Creatinine (2.2 mg/dl) and BUN (37 mg/dl) levels remain stable. No acute or chronic radiation-induced toxicities were noted 9 months following treatment.

Conclusion and CyberKnife Advantages

This patient had an excellent initial outcome with CyberKnife using Synchrony motion compensation in the treatment of renal cell carcinoma, while preserving renal function of the right remaining kidney.

CyberKnife can deliver complex treatment plans to multiple lesions while minimizing irradiation to the surrounding healthy tissue, thereby decreasing the risk of complications.

CyberKnife has the potential to be an excellent treatment modality for renal cancer patients with renal cell carcinomas or patients with bilateral renal cell carcinoma who refuse surgery or are medically inoperable.

References:
Case History
This 75 year-old male presented with abdominal pain. He had a medical history of hypertension & coronary artery disease and a surgical history including triple bypass, cardiac stent placement, partial colectomy for diverticulitis, and multiple laminectomies. Abdominal CT revealed a 7.5 x 8.0 cm mass in the lower pole of the left kidney and a 4.7 x 4.1 cm mass in the mid to upper pole of the right kidney, felt to be consistent with bilateral renal cell carcinoma. A bone scan revealed no indications of metastatic disease and chest CT was normal.

The patient underwent embolization of the left renal artery followed by left radical nephrectomy for the large left renal mass. Upon pathological examination, the mass proved to be a clear cell carcinoma involving the renal capsule, renal parenchyma and large blood vessels. The patient was staged as T3a, N0, M0. The patient had a prolonged post-operative course because of gastroparesis and new onset of gouty arthritis, which gradually resolved. Post-operatively the patient was noted to have an elevated serum creatinine of 2.1 mg/dl and elevated BUN level of 49 mg/dl. Subsequent CT revealed 2 lesions in the right remaining kidney, a large superior mass measuring 86.4 cm³ and a 2.8 cm³ inferior lesion. The patient underwent CT-guided biopsy of the right renal mass which confirmed clear cell renal cell carcinoma, Fuhrman Grade I-II.

CyberKnife Treatment Rationale
The patient was evaluated by surgery and radiation oncology for his right renal cell carcinoma. The patient was not considered a good candidate for partial nephrectomy due to his recent history of his left nephrectomy, elevated post-operative renal function tests and multiple co-morbidities putting him at high risk for dialysis. High dose-per-fraction, conformal stereotactic radiosurgery has been shown to achieve local control of small renal cell carcinomas. Pre-clinical studies have demonstrated that hypofractionation schemes delivered by the CyberKnife® can ablate renal cell carcinomas in vivo. Furthermore, renal cell carcinoma metastases to the spine have been responsive to CyberKnife radiosurgery. In this case, the patient refused surgery and opted for CyberKnife treatment of the right renal masses.
Treatment Planning Process
The patient was prepared for planning as follows: i) 5 fiducials were placed around the right renal masses using CT guidance ii) planning CT image was obtained with patient in the prone position using an alpha cradle for immobilization. Fiducials were identified and the right superior and inferior lesions were outlined on the scans resulting in target volumes of 86.4 cm³ and 2.8 cm³ respectively. A treatment plan was developed which combined treatment plans for the large and small tumors into a composite plan. The final plan was created to deliver 30 Gy in 3 fractions to the 72% isodose line at the margin of the tumor using both the 7.5 and 20 mm collimators.

Treatment Delivery
The patient underwent CyberKnife® treatment which consisted of 10 Gy times 3 fractions using 282 beams from 77 nodes. The prescribed dose covered 98.7% of the combined target volumes with a homogeneity index score of 1.39 and a conformality index score of 1.39. The amount of remaining normal kidney was maximally spared and the patient tolerated the procedure well.

Dose Volume Histogram (DVH) for 86.4 cm³ (red) and 2.8 cm³ (green) lesions.
Outcome and Follow-Up

- Three months after CyberKnife treatment, CT scan of the abdomen revealed an unchanged 3-4 cm lesion in the upper pole of the right kidney with no evidence of retroperitoneal adenopathy. There was no evidence of recurrent tumor in the left renal fossa. A PET scan confirmed no evidence of metastatic disease. Creatinine (2.3 mg/dl) and BUN (36 mg/dl) levels remained stable.
- Nine months after CyberKnife treatment, the patient had a CT scan revealing an unchanged 4 cm low density mass located in the upper pole of the right kidney and a negative chest X-ray. Creatinine (2.2 mg/dl) and BUN (37 mg/dl) levels remain stable. No acute or chronic radiation-induced toxicities were noted 9 months following treatment.

Conclusion and CyberKnife Advantages

- This patient had an excellent initial outcome with CyberKnife using Synchrony motion compensation in the treatment of renal cell carcinoma, while preserving renal function of the right remaining kidney.
- CyberKnife can deliver complex treatment plans to multiple lesions while minimizing irradiation to the surrounding healthy tissue, thereby decreasing the risk of complications.
- CyberKnife has the potential to be an excellent treatment modality for renal cancer patients with renal cell carcinomas or patients with bilateral renal cell carcinoma who refuse surgery or are medically inoperable.

ST. JOSEPH’S HOSPITAL AND MEDICAL CENTER / BARROW NEUROLOGICAL INSTITUTE

St. Joseph’s Hospital and Medical Center/Barrow Neurological Institute, Phoenix, AZ (www.stjosephs-phx.org) is a highly regarded 690 bed not-for-profit medical center founded in 1895 by the Sisters of Mercy and is part of the Catholic Healthcare West (CHW) system. Dr. Kresl, the Co-Medical Director of the St. Joseph’s Barrow Neurological Institute’s CyberKnife Center and a member of Arizona Oncology Services, one of the largest radiation oncology treatment programs in the Southwest, actively participates in national and regional Clinical Oncology Treatment Protocols that offer the newest and most advanced forms of treatment for tumors of all disease sites. CyberKnife radiosurgery began at St. Joseph’s Hospital and Medical Center/Barrow Neurological Institute in September 2003. The CyberKnife is used on those patients for whom traditional radiosurgery is not possible or in situations where patients specifically request this procedure over other treatment.

References